News

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Isturisa (osilodrostat) to treat people with endogenous Cushing’s syndrome for whom pituitary brain surgery has not been effective or is not an option. Recordati…

Recorlev (levoketoconazole), Strongbridge Biopharma’s oral candidate to treat endogenous Cushing’s syndrome, was superior to a placebo at lowering cholesterol levels and body mass index, a measure of body fat, according to newly released data from the pivotal Phase 3 LOGICS trial. These findings, concerning most of the trial’s…

Isturisa (osilodrostat), an approved oral therapy for Cushing’s disease, can rapidly normalize — in a median of 35 days — the levels of urine free cortisol in people with the disease, according to newly released data from the Phase 3 LINC-4 trial. Treatment also led to sustained improvements in…

Endoscopic transsphenoidal surgery (ETSS), a minimally invasive procedure that allows surgeons to remove pituitary tumors in people with Cushing’s disease, is associated with good remission rates, according to a recent study. The study, “Outcomes of endoscopic transsphenoidal surgery for Cushing’s disease,” was published in the journal BMC Endocrine…

HRA Pharma Rare Diseases is providing an unrestricted educational grant to fund “Cushing’s Hub,” a first-of-its-kind online platform designed to help healthcare providers care for patients with Cushing’s syndrome. The Hub, developed by Springer Healthcare Education, will provide information to promote good clinical practice, and improve diagnosis and…

Although rare, Cushing’s disease associated with a tumor in the pituitary gland — a pea-size gland found deep within the brain — may occur in patients who also have a meningioma, a type of tumor that arises from the membranes that cover the brain within the skull, a case…

Strongbridge Biopharma has filed an application with the U.S. Food and Drug Administration (FDA) seeking the approval of Recorlev (levoketoconazole) to treat people with endogenous Cushing’s syndrome, the company announced. The application is supported by results from two Phase 3 studies, SONICS (NCT01838551) and LOGICS (NCT03277690), which showed…

Disruptions in blood sugar metabolism and hypercortisolism — excessive levels of the hormone cortisol in the blood — are both linked to a higher risk of hyperlipidemia, or having high levels of fatty molecules circulating in the bloodstream, in people with Cushing’s disease, a study found. Hyperlipidemia, in turn,…